224 related articles for article (PubMed ID: 14734761)
1. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects.
Storni T; Ruedl C; Schwarz K; Schwendener RA; Renner WA; Bachmann MF
J Immunol; 2004 Feb; 172(3):1777-85. PubMed ID: 14734761
[TBL] [Abstract][Full Text] [Related]
2. Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
Storni T; Lechner F; Erdmann I; Bächi T; Jegerlehner A; Dumrese T; Kündig TM; Ruedl C; Bachmann MF
J Immunol; 2002 Mar; 168(6):2880-6. PubMed ID: 11884458
[TBL] [Abstract][Full Text] [Related]
3. Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison.
Storni T; Bachmann MF
J Immunol; 2004 May; 172(10):6129-35. PubMed ID: 15128799
[TBL] [Abstract][Full Text] [Related]
4. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
5. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
Davila E; Celis E
J Immunol; 2000 Jul; 165(1):539-47. PubMed ID: 10861094
[TBL] [Abstract][Full Text] [Related]
6. Role of Toll-like receptors in costimulating cytotoxic T cell responses.
Schwarz K; Storni T; Manolova V; Didierlaurent A; Sirard JC; Röthlisberger P; Bachmann MF
Eur J Immunol; 2003 Jun; 33(6):1465-70. PubMed ID: 12778463
[TBL] [Abstract][Full Text] [Related]
7. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge.
Daftarian P; Ali S; Sharan R; Lacey SF; La Rosa C; Longmate J; Buck C; Siliciano RF; Diamond DJ
J Immunol; 2003 Oct; 171(8):4028-39. PubMed ID: 14530323
[TBL] [Abstract][Full Text] [Related]
8. Non-methylated CpG motif packaged into fusogenic liposomes enhance antigen-specific immunity in mice.
Yoshikawa T; Imazu S; Gao JQ; Hayashi K; Tsuda Y; Okada N; Tsutsumi Y; Akashi M; Mayumi T; Nakagawa S
Biol Pharm Bull; 2006 Jan; 29(1):105-9. PubMed ID: 16394520
[TBL] [Abstract][Full Text] [Related]
9. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
[TBL] [Abstract][Full Text] [Related]
10. Augmented induction of CD8+ cytotoxic T-cell response and antitumor effect by DCs pulsed with virus-like particles packaging with CpG.
Song S; Wang Y; Zhang Y; Wang F; He Y; Ren D; Guo Y; Sun S
Cancer Lett; 2007 Oct; 256(1):90-100. PubMed ID: 17656012
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA vaccines to myeloid cells using a small peptide.
Ye C; Choi JG; Abraham S; Shankar P; Manjunath N
Eur J Immunol; 2015 Jan; 45(1):82-8. PubMed ID: 25270431
[TBL] [Abstract][Full Text] [Related]
12. Innate immunity together with duration of antigen persistence regulate effector T cell induction.
Storni T; Ruedl C; Renner WA; Bachmann MF
J Immunol; 2003 Jul; 171(2):795-801. PubMed ID: 12847247
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine.
Kojima Y; Xin KQ; Ooki T; Hamajima K; Oikawa T; Shinoda K; Ozaki T; Hoshino Y; Jounai N; Nakazawa M; Klinman D; Okuda K
Vaccine; 2002 Jul; 20(23-24):2857-65. PubMed ID: 12126895
[TBL] [Abstract][Full Text] [Related]
14. Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.
You Z; Huang XF; Hester J; Rollins L; Rooney C; Chen SY
J Immunol; 2000 Oct; 165(8):4581-91. PubMed ID: 11035100
[TBL] [Abstract][Full Text] [Related]
15. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines.
Rice J; Elliott T; Buchan S; Stevenson FK
J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377
[TBL] [Abstract][Full Text] [Related]
16. Activation of dendritic cells and induction of T cell responses by HPV 16 L1/E7 chimeric virus-like particles are enhanced by CpG ODN or sorbitol.
Freyschmidt EJ; Alonso A; Hartmann G; Gissmann L
Antivir Ther; 2004 Aug; 9(4):479-89. PubMed ID: 15456078
[TBL] [Abstract][Full Text] [Related]
17. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen.
Davis HL; Weeratna R; Waldschmidt TJ; Tygrett L; Schorr J; Krieg AM
J Immunol; 1998 Jan; 160(2):870-6. PubMed ID: 9551923
[TBL] [Abstract][Full Text] [Related]
18. Antiviral protection after DNA vaccination is short lived and not enhanced by CpG DNA.
Oehen S; Junt T; López-Macías C; Kramps TA
Immunology; 2000 Feb; 99(2):163-9. PubMed ID: 10692032
[TBL] [Abstract][Full Text] [Related]
19. CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines.
Oxenius A; Martinic MM; Hengartner H; Klenerman P
J Virol; 1999 May; 73(5):4120-6. PubMed ID: 10196308
[TBL] [Abstract][Full Text] [Related]
20. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP.
Ruedl C; Storni T; Lechner F; Bächi T; Bachmann MF
Eur J Immunol; 2002 Mar; 32(3):818-25. PubMed ID: 11870626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
